Metabolite Profiling of Danatinib in Mice Using Ultra-High-Performance Liquid Chromatography/Tandem Mass Spectrometry...

Area of Science:

• Pharmacology
• Drug Metabolism
• Medicinal Chemistry

Background:

• Danatinib shows promise for acute myeloid leukemia (AML) treatment.
• Its short pharmacokinetic profile (half-life of 0.476 h) limits therapeutic efficacy.
• Optimizing Danatinib's metabolism is crucial for enhancing its clinical application.

Purpose of the Study:

• To systematically investigate the metabolic profiles of Danatinib in mice.
• To identify Danatinib metabolites formed through various metabolic pathways.
• To provide data for structural modifications to improve Danatinib's pharmacokinetic properties.

Main Methods:

• In vitro analysis using mouse liver microsomes.
• In vivo analysis of plasma, bile, feces, and urine samples from orally administered mice.
• Ultra-high-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UHPLC/Q-TOF MS) for metabolite identification.

Main Results:

• Eight Danatinib metabolites were identified in vitro.
• Thirty-four Danatinib metabolites were identified in vivo.
• Metabolites were formed via hydroxylation, carboxylation, acetylation, hydrogenation, and glucuronidation.

Conclusions:

• This study provides a comprehensive metabolic profile of Danatinib in mice.
• Understanding Danatinib's metabolism is key to improving its pharmacokinetic characteristics.
• The findings support further research into structural modifications for enhanced therapeutic efficacy in AML.